Sotagliflozin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sotagliflozin
Accession Number
DB12713
Type
Small Molecule
Groups
Investigational
Description

Sotagliflozin has been used in trials studying the treatment of Renal impairment, Hepatic Impairment, Type 1 Diabetes Mellitus, and High Level of Sugar (Glucose) in the Blood.

Structure
Thumb
Synonyms
Not Available
External IDs
LP-802034
Categories
UNII
6B4ZBS263Y
CAS number
1018899-04-1
Weight
Average: 424.94
Monoisotopic: 424.1111228
Chemical Formula
C21H25ClO5S
InChI Key
QKDRXGFQVGOQKS-CRSSMBPESA-N
InChI
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(methylsulfanyl)oxane-3,4,5-triol
SMILES
CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Sotagliflozin.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Sotagliflozin.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Sotagliflozin.
AcetazolamideThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Sotagliflozin.
Acetyl sulfisoxazoleThe therapeutic efficacy of Sotagliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Sotagliflozin.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Sotagliflozin.
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Sotagliflozin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24831714
PubChem Substance
347828911
ChemSpider
27289071
ChEMBL
CHEMBL3039507

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedBasic ScienceDiabetes Mellitus (DM)2
1CompletedHealth Services ResearchDiabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
1CompletedTreatmentDiabetes Mellitus (DM)1
1CompletedTreatmentHealthy Volunteers / Hepatic Impairment1
1CompletedTreatmentHealthy Volunteers / Impaired Renal Function1
1CompletedTreatmentHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedTreatmentType 2 Diabetes Mellitus3
1Not Yet RecruitingTreatmentDiabetes Mellitus (DM)1
1RecruitingBasic ScienceDiabetes Mellitus (DM) / Healthy Volunteers1
1RecruitingTreatmentHealthy Volunteers / Type 2 Diabetes Mellitus1
2Active Not RecruitingTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
2RecruitingTreatmentCardiac Failure Aggravated1
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus7
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus-Chronic Kidney Disease Stage 31
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus-Chronic Kidney Disease Stage 41
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / High Level of Sugar (Glucose) in the Blood1
3RecruitingPreventionChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1
3RecruitingTreatmentHeart Failure-Type 2 Diabetes Mellitus1
3RecruitingTreatmentType 2 Diabetes Mellitus2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.042 mg/mLALOGPS
logP3.19ALOGPS
logP3.73ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)12.47ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area79.15 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.87 m3·mol-1ChemAxon
Polarizability44.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Diphenylmethanes / Thioglycosides / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Oxanes / Monosaccharides / Monothioacetals
show 6 more
Substituents
Phenolic glycoside / Diphenylmethane / S-glycosyl compound / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Oxane / Benzenoid
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:45 / Updated on November 02, 2018 07:28